Holen Sie sich die Stockscreener-App
2.95
5.73%
0.16
Handel nachbörslich:
2.94
-0.01
-0.34%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.79
Offen:
$2.84
24-Stunden-Volumen:
6.41M
Relative Volume:
0.95
Marktkapitalisierung:
$594.79M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-1.3915
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
-0.34%
1M Leistung:
+4.61%
6M Leistung:
+224.64%
1J Leistung:
+22.41%
1-Tages-Spanne:
$2.82
$3.02
1-Wochen-Bereich:
$2.66
$3.05
52-Wochen-Spanne:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Vergleichen Sie ESPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.95 | 661.42M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Is Esperion Therapeutics Inc. stock a safe investment in uncertain markets2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - newser.com
Will Esperion Therapeutics Inc. stock recover faster than marketTreasury Yields & Daily Profit Focused Screening - newser.com
Esperion: HLS Therapeutics (TSX:HLS) Secures Health Canada Clearance for NILEMDO® - Kalkine Media
Is Esperion Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Action & Pattern Based Trade Signal System - newser.com
Why Esperion Therapeutics Inc. is moving todayMarket Movement Recap & Expert Verified Movement Alerts - newser.com
Multi asset correlation models including Esperion Therapeutics Inc.Portfolio Return Summary & Low Drawdown Momentum Ideas - newser.com
Will Esperion Therapeutics Inc. stock outperform international peersQuarterly Earnings Summary & Stepwise Trade Execution Plans - newser.com
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Esperion (NASDAQ: ESPR) to Present at Piper Sandler 37th Annual Healthcare Conference - Stock Titan
Can Esperion Therapeutics Inc. stock double in next 5 yearsJuly 2025 Retail & Safe Swing Trade Setups - newser.com
Will earnings trigger a reversal in Esperion Therapeutics Inc.2025 Technical Overview & Smart Investment Allocation Insights - newser.com
Esperion’s cholesterol drug Nilemdo receives Health Canada approval By Investing.com - Investing.com Nigeria
Esperion partner announces HLS Therapeutics received approval of Nilemdo for the reduction of LDL cholesterol in Canadians at risk of cardiovascular disease - MarketScreener
Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease - TradingView
HLS Therapeutics Receives Health Canada Approval to Market NILEMDO® for LDL-Cholesterol Reduction in Partnership with Esperion - Quiver Quantitative
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease - The Manila Times
Esperion Partner HLS Therapeutics Announces Approval of - GlobeNewswire
Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
[Form 3] Esperion Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Relative strength of Esperion Therapeutics Inc. in sector analysisInflation Watch & Breakout Confirmation Alerts - newser.com
Why retail investors favor Esperion Therapeutics Inc. stockRisk Management & Free Expert Verified Stock Movement Alerts - newser.com
Is Esperion Therapeutics Inc. stock reversal real or fake2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
Can volume confirm reversal in Esperion Therapeutics Inc.Swing Trade & Free Expert Verified Stock Movement Alerts - newser.com
Identifying reversal signals in Esperion Therapeutics Inc.July 2025 Macro Moves & Capital Protection Trading Alerts - newser.com
How to integrate Esperion Therapeutics Inc. into portfolio analysis toolsJuly 2025 Trends & Consistent Profit Trade Alerts - newser.com
Can Esperion Therapeutics Inc. stock deliver surprise earnings beatTrend Reversal & Free Reliable Trade Execution Plans - newser.com
Smart tools for monitoring Esperion Therapeutics Inc.’s price actionWeekly Profit Recap & Precise Swing Trade Entry Alerts - newser.com
Esperion Therapeutics Reports Strong Q3 Revenue Growth - MSN
ESPR | Esperion Therapeutics Inc. SEC Filings - MarketWatch
How Esperion Therapeutics Inc. stock benefits from global expansionWeekly Risk Report & Stock Market Timing Techniques - newser.com
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.17%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):